Here is the detailed profile of the Buprenorphine 2 mg + Naloxone 0.5 mg Sublingual Tablet โ without brand names:
๐ Buprenorphine 2 mg + Naloxone 0.5 mg (Sublingual Tablet)
โ DESCRIPTION
This fixed-dose combination is used for the treatment of opioid dependence.
- Buprenorphine: A partial opioid agonist, reduces cravings and withdrawal symptoms.
- Naloxone: An opioid antagonist, included to deter misuse (especially injection abuse).
When taken sublingually, naloxone has minimal activity, but if injected, it can precipitate withdrawal.
๐งช FORMULATION
- Buprenorphine hydrochloride equivalent to 2 mg
- Naloxone hydrochloride equivalent to 0.5 mg
- Dosage form: Sublingual tablet
- Route: Sublingual (under the tongue)
๐ฟ NATURE
- Buprenorphine: Partial ยต-opioid receptor agonist; ฮบ-receptor antagonist
- Naloxone: Competitive ยต-opioid receptor antagonist
๐ USES
- Opioid dependence treatment, both initiation and maintenance
- Harm reduction by reducing illicit opioid use
- Helps patients transition to recovery under medical supervision
๐ ADVANTAGES
- Reduces cravings and withdrawal without producing intense euphoria
- Naloxone prevents IV misuse
- Safer profile than full agonists (like morphine or heroin)
- May be used in outpatient-based de-addiction programs
โ ๏ธ PRECAUTIONS
Common Side Effects:
- Headache, sweating, mouth numbness
- Sleep disturbances, constipation, nausea
- Anxiety or mood changes
Serious Risks:
- Respiratory depression (especially with CNS depressants)
- Liver function abnormalities
- Precipitated withdrawal if initiated too early after last opioid use
- Dependence and misuse if not monitored
โ CONTRAINDICATIONS
- Allergy to buprenorphine or naloxone
- Severe respiratory or hepatic impairment
- Concurrent alcohol or sedative overdose
๐ฉโโ๏ธ SPECIAL POPULATIONS
- Pregnancy: Use with caution โ may cause neonatal withdrawal
- Breastfeeding: Buprenorphine may pass into milk in small amounts
- Elderly: Dose adjustment may be needed
- Pediatrics: Not recommended under 16 years
๐ DRUG INTERACTIONS
- Alcohol, benzodiazepines, and CNS depressants โ โ risk of sedation and respiratory depression
- CYP3A4 inhibitors (e.g., ketoconazole) โ โ buprenorphine levels
- CYP3A4 inducers (e.g., carbamazepine) โ โ effectiveness
- May interact with SSRIs, antihypertensives, and MAOIs
๐ก ADMINISTRATION GUIDELINES
- Place tablet under the tongue until fully dissolved
- Do not chew, crush, swallow, or inject
- Avoid eating/drinking until absorption is complete
- First dose should be medically supervised
- Avoid abrupt discontinuation to prevent withdrawal
๐ง STORAGE
- Store at 20โ25ยฐC (68โ77ยฐF)
- Keep in original, moisture-resistant packaging
- Controlled substance โ secure storage required
- Keep away from children